Detalhe da pesquisa
1.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
2.
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
Hematol Oncol
; 42(2): e3258, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402467
3.
Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma.
Acta Haematol
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38657575
4.
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Blood
; 137(26): 3616-3628, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33763699
5.
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
Hematol Oncol
; 41(3): 442-452, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433829
6.
Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment.
Ann Hematol
; 102(6): 1477-1483, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37115297
7.
Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma.
Ann Hematol
; 102(9): 2493-2504, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37341778
8.
Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies.
Ann Hematol
; 102(12): 3489-3497, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37668787
9.
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Ann Hematol
; 102(4): 863-876, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36862168
10.
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
Am J Hematol
; 98(5): 720-729, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36708469
11.
Once Monthly Elotuzumab and Lenalidomide Plus Dexamethasone for Multiple Myeloma: A Multicenter Observation Study.
Acta Haematol
; 146(2): 125-136, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36538896
12.
[Optimal safety management procedures for medications with potent teratogenic properties: a prospective intervention cluster randomized non-inferiority comparative study].
Rinsho Ketsueki
; 64(3): 175-186, 2023.
Artigo
em Japonês
| MEDLINE | ID: mdl-37019670
13.
[A retrospective analysis of 124 patients with multiple myeloma who received up-front autologous hematopoietic cell transplantation following triplet induction therapy].
Rinsho Ketsueki
; 64(11): 1397-1403, 2023.
Artigo
em Japonês
| MEDLINE | ID: mdl-38072424
14.
Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia.
Cancer Sci
; 113(6): 2085-2096, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35332633
15.
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
Cancer Sci
; 113(12): 4267-4276, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36052883
16.
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Lancet
; 397(10292): 2361-2371, 2021 06 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097854
17.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293006
18.
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
Br J Haematol
; 194(1): 132-139, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33822368
19.
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Br J Haematol
; 192(5): 869-878, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33216361
20.
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Lancet
; 395(10218): 132-141, 2020 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31836199